James J Cummings1, Satyan Lakshminrusimha. 1. aDepartment of Pediatrics, The Children's Hospital at Albany Medical Center, Albany bDepartment of Pediatrics, Women and Children's Hospital of Buffalo, Buffalo, New York, New York, USA.
Abstract
PURPOSE OF REVIEW: A collaboration of comparative effectiveness research trials of pulse oximeter saturation (SpO2) targeting in extremely low-gestational-age neonates have begun to report their aggregate results. We examine the results of those trials, collectively referred to as the Neonatal Oxygenation Prospective Meta-analysis or NeOProM. We also discuss the uncertainties that remain and the clinical challenges that lie ahead. RECENT FINDINGS: The primary outcome from NeOProM was a composite of death or disability at 18-24 months corrected age. In 2016 the last of these reports was published. Although there were no differences in the primary outcome overall, analyses of secondary outcomes and data subsets following a pulse oximeter revision show significant treatment differences between targeting a lower compared with a higher SpO2. SUMMARY: NeOProM represents the largest collaborative clinical research study of SpO2 targets in extremely low-gestational-age neonates. Although aggregate results give us some insight into the feasibility and efficacy of SpO2 targeting in this population, many questions remain. A patient-level analysis, tracking individual outcomes based on actual SpO2 experienced, may shed some light on these questions. However, finding a single optimal SpO2 range seems unlikely.
PURPOSE OF REVIEW: A collaboration of comparative effectiveness research trials of pulse oximeter saturation (SpO2) targeting in extremely low-gestational-age neonates have begun to report their aggregate results. We examine the results of those trials, collectively referred to as the Neonatal Oxygenation Prospective Meta-analysis or NeOProM. We also discuss the uncertainties that remain and the clinical challenges that lie ahead. RECENT FINDINGS: The primary outcome from NeOProM was a composite of death or disability at 18-24 months corrected age. In 2016 the last of these reports was published. Although there were no differences in the primary outcome overall, analyses of secondary outcomes and data subsets following a pulse oximeter revision show significant treatment differences between targeting a lower compared with a higher SpO2. SUMMARY: NeOProM represents the largest collaborative clinical research study of SpO2 targets in extremely low-gestational-age neonates. Although aggregate results give us some insight into the feasibility and efficacy of SpO2 targeting in this population, many questions remain. A patient-level analysis, tracking individual outcomes based on actual SpO2 experienced, may shed some light on these questions. However, finding a single optimal SpO2 range seems unlikely.
Authors: Brian A Darlow; Simone L Marschner; Mark Donoghoe; Malcolm R Battin; Roland S Broadbent; Mark J Elder; Michael P Hewson; Michael P Meyer; Alpana Ghadge; Patricia Graham; Nicolette J McNeill; Carl A Kuschel; William O Tarnow-Mordi Journal: J Pediatr Date: 2014-02-20 Impact factor: 4.406
Authors: David G Sweet; Virgilio Carnielli; Gorm Greisen; Mikko Hallman; Eren Ozek; Richard Plavka; Ola Didrik Saugstad; Umberto Simeoni; Christian P Speer; Máximo Vento; Gerard H A Visser; Henry L Halliday Journal: Neonatology Date: 2016-09-21 Impact factor: 4.035
Authors: Juliann M Di Fiore; Richard J Martin; Hong Li; Nathan Morris; Waldemar A Carlo; Neil Finer; Michele Walsh Journal: J Pediatr Date: 2017-03-06 Impact factor: 4.406
Authors: Michele C Walsh; Juliann M Di Fiore; Richard J Martin; Marie Gantz; Waldemar A Carlo; Neil Finer Journal: JAMA Pediatr Date: 2016-03 Impact factor: 16.193
Authors: Waldemar A Carlo; Neil N Finer; Michele C Walsh; Wade Rich; Marie G Gantz; Abbot R Laptook; Bradley A Yoder; Roger G Faix; Abhik Das; W Kenneth Poole; Kurt Schibler; Nancy S Newman; Namasivayam Ambalavanan; Ivan D Frantz; Anthony J Piazza; Pablo J Sánchez; Brenda H Morris; Nirupama Laroia; Dale L Phelps; Brenda B Poindexter; C Michael Cotten; Krisa P Van Meurs; Shahnaz Duara; Vivek Narendran; Beena G Sood; T Michael O'Shea; Edward F Bell; Richard A Ehrenkranz; Kristi L Watterberg; Rosemary D Higgins Journal: N Engl J Med Date: 2010-05-16 Impact factor: 91.245
Authors: Thomas E Bachman; Narayan P Iyer; Christopher J L Newth; Patrick A Ross; Robinder G Khemani Journal: BMC Pediatr Date: 2020-06-27 Impact factor: 2.125